Clinical Trial Update: FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating FOLFOX with Bevacizumab for metastatic or unresectable gastroesophageal and gastric cancer; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• FLUOROURACIL (Fluorouracil)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Yale University | Conditions: Gastroesophageal Cancer, Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-07-14